#VisualAbstract: Addition of elotuzumab to lenalidomide and dexamethasone did not significantly improve survival outcomes in newly diagnosed, transplant-ineligible multiple myeloma byKathleen Lau May 19, 2022 0
#VisualAbstract: Daratumumab-based therapies were associated with higher rates of sustained minimal residual disease negativity in patients with newly diagnosed multiple myeloma byKathleen Lau February 3, 2022 0
#VisualAbstract An ixazomib-based regimen may be a better-tolerated approach in elderly patients with newly diagnosed multiple myeloma byKathleen Lau December 18, 2021 0
#VisualAbstract Addition of daratumumab to standard of care improves minimal residual disease negativity in patients with newly diagnosed, transplant-ineligible multiple myeloma byKathleen Lau July 23, 2021 0
#VisualAbstract TOURMALINE-MM2 trial: Oral ixazomib, lenalidomide, and dexamethasone is a feasible and well-tolerated all-oral regimen in non-transplant, newly diagnosed multiple myeloma byKathleen Lau April 1, 2021 0
#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed byKathleen Lau March 25, 2021 0
#VisualAbstract CARDAMON case series: Thrombotic microangiopathy in newly diagnosed multiple myeloma patients receiving carfilzomib, cyclophosphamide, and dexamethasone can be preventatively managed byKathleen Lau March 12, 2021 0
#VisualAbstract Lenalidomide shows improvement in progression-free survival over bortezomib maintenance following autologous stem cell transplantation for multiple myeloma byKathleen Lau January 28, 2021 0
#VisualAbstract Administering bortezomib on a weekly basis VS twice weekly basis does not significantly affect progression-free survival (PFS) or overall survival (OS) in Vrd first-line therapy for multiple myeloma (bortezomib, lenalidomide, and dexamethasone) byKathleen Lau January 1, 2021 0
